Palisade Bio Inc
PALI
Get informed when a big investor buys or sells
+ FollowMarket Cap$364.52M
Close$
$2.39
17.4% upside
Current Fair Value
17.4% upsideUndervalued by 17.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $364.52 Million |
|---|---|
| Enterprise Value | $239.35 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.3 |
| Beta | 1.54 |
| Outstanding Shares | 211,381,969 |
Return
| Return on Equity | -26.24% |
|---|---|
| Return on Assets | -25.09% |
| Return on Invested Capital | -28.15% |
Valuation & Multiples
| P/E Ratio | -3.95 |
|---|---|
| PEG | -1.41 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 478.69 |
| Enterprise Value to EBIT | -6.96 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$465,302
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 268.53%▲ 24.45% |
|---|---|
| Total Invested | $261.72M▼ 18.05% |
| Investors Holding | 95▲ 9.00% |
ESG Score
No data
About Palisade Bio Inc
7 employees
CEO: I. Richard Garr Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB114...